Structural Studies and Drug Discovery Illuminate Serotonin Pharmacology
结构研究和药物发现阐明了血清素药理学
基本信息
- 批准号:9797377
- 负责人:
- 金额:$ 39.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-01 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:Amphetamine AbuseAmphetaminesArchitectureBindingBinding SitesBiologicalBiologyCardiovascular systemChemicalsCognitionCoupledCryoelectron MicroscopyCrystallizationCrystallographyDevelopmentDiabetes MellitusDiseaseDrug ModulationDrug TargetingDrug effect disorderEndocrineFutureGTP-Binding ProteinsGoalsHumanIn VitroLigand BindingMediatingMedicalMolecularMolecular ConformationMolecular TargetMoodsNeurotransmittersPharmaceutical PreparationsPharmacologyPhysiologicalPhysiologyReceptor ActivationRegulationRoleSerotoninSignal TransductionStructureTherapeuticbasecell motilitydrug discoveryin vivoinnovationinsightmedication safetyneglectnew therapeutic targetnovelprotein activationreceptorserotonin receptorserotonin transportertoolvesicular monoamine transporter 2
项目摘要
Project Summary/Abstract
The main goal of the lab is to provide detailed structural and functional insight into serotonin signaling and
transport, and elucidate how drugs and medications modulate receptor and transporter function. Serotonin (5-
hydroxytryptamine, 5-HT) regulates much of human physiology in- and outside the CNS, including cognition,
mood, endocrine function and cardiovascular development. However, despite 5-HT's physiological and medical
importance, atomic-level insight into the mechanisms of 5-HT signaling and transport, and how drugs interact
with these molecular targets, has remained largely elusive. This lack of understanding has led to drug safety
issues in the past, and greatly hindered the exploration of many 5-HT targets for novel therapeutic applications.
Our lab is thus focused on two grossly understudied 5-HT targets. The first major direction of the lab is to
elucidate ligand binding and activation of the 5-HT1E receptor, the least understood 5-HT receptor whose
physiological role is unknown. Unlike for all other 5-HT receptors, there are no selective compounds for 5-
HT1ER, which raises important questions about the molecular architecture of its binding pocket and
mechanisms of receptor activation. To answer these questions, we will determine the cryoEM structure of G
protein-coupled 5-HT1ER, which will provide detailed structural insight into the ligand binding pocket
architecture, and the receptor's conformational changes responsible for G protein activation. The second major
project is focused on the vesicular monoamine transporter 2 (VMAT2), an essential transporter for storage and
regulation of neurotransmitter signaling, and target for a variety of disorders from diabetes to amphetamine
abuse. Despite its biological and medical significance, there is a lack of atomic-level insight into where and
how substrates, drugs, or medications bind, or how they modulate VMAT2 function. We will therefore
determine crystal structures of VMAT2 bound to various substrates and drugs, elucidate fundamental
mechanisms of transport and drug modulation, and characterize the precise architecture of different binding
sites. We will further use our molecular insights in structure-based drug discovery, to develop
pharmacologically and chemically novel tool compounds for future studies of VMAT2 (patho)biology in in vitro
and in vivo. Our studies are both innovative technically and conceptually, as the unique combination of
structural, pharmacological, and drug discovery approaches will provide an unprecedented view into the
molecular mechanisms of two neglected and understudied 5-HT drug targets.
项目总结/摘要
该实验室的主要目标是提供对血清素信号传导的详细结构和功能见解,
运输,并阐明如何药物和药物调节受体和转运功能。血清素(5-
羟色胺,5-HT)调节CNS内外的许多人体生理学,包括认知,
情绪、内分泌功能和心血管发育。然而,尽管5-HT的生理和医学
重要性,对5-HT信号传导和转运机制以及药物如何相互作用的原子水平洞察
与这些分子靶点的结合,仍然很难实现。这种缺乏了解导致了药物安全
过去的问题,并大大阻碍了许多5-HT新的治疗应用的目标的探索。
因此,我们的实验室专注于两个严重研究不足的5-HT靶点。实验室的第一个主要方向是
阐明5-HT 1 E受体的配体结合和活化,5-HT 1 E受体是最不了解的5-HT受体,
生理作用未知。与所有其他5-HT受体不同,没有5-HT受体的选择性化合物。
HT 1 ER,这提出了关于其结合口袋的分子结构的重要问题,
受体激活机制。为了回答这些问题,我们将确定G
蛋白偶联的5-HT 1 ER,这将提供详细的结构洞察配体结合口袋
结构,以及负责G蛋白激活的受体构象变化。第二主
该项目的重点是囊泡单胺转运蛋白2(VMAT 2),这是一种重要的储存转运蛋白,
调节神经递质信号传导,并针对从糖尿病到安非他明的各种疾病
虐待尽管它在生物学和医学上具有重要意义,但缺乏原子水平的洞察力,
底物、药物或药物如何结合,或它们如何调节VMAT 2功能。因此我们将
确定与各种底物和药物结合的VMAT 2的晶体结构,阐明VMAT 2的基本原理,
转运和药物调节的机制,并表征不同结合的精确结构
网站.我们将进一步利用我们在基于结构的药物发现中的分子见解,
用于未来体外研究VMAT 2(病理)生物学的生物学和化学新工具化合物
和体内。我们的研究在技术上和概念上都是创新的,
结构,药理学和药物发现方法将提供一个前所未有的观点,
两个被忽视和研究不足的5-HT药物靶点的分子机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Daniel Wacker其他文献
Daniel Wacker的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Daniel Wacker', 18)}}的其他基金
Structural Studies and Drug Discovery Illuminate Serotonin Pharmacology
结构研究和药物发现阐明了血清素药理学
- 批准号:
10396020 - 财政年份:2019
- 资助金额:
$ 39.6万 - 项目类别:
Structural Studies and Drug Discovery Illuminate Serotonin Pharmacology
结构研究和药物发现阐明了血清素药理学
- 批准号:
10605204 - 财政年份:2019
- 资助金额:
$ 39.6万 - 项目类别:
相似海外基金
Relationship between neurotoxicity and the chemical structures of amphetamines
安非他明的神经毒性与化学结构的关系
- 批准号:
25860103 - 财政年份:2013
- 资助金额:
$ 39.6万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Search for protein expression in amphetamines treated mouse heart : Challenge to the diagnosis for the sudden death of amphetamines abusers
寻找安非他明治疗小鼠心脏中的蛋白质表达:对安非他明滥用者猝死诊断的挑战
- 批准号:
22659138 - 财政年份:2010
- 资助金额:
$ 39.6万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
用于治疗安非他明滥用/疾病的新型功能选择性血清素 5HT2 药物
- 批准号:
8312648 - 财政年份:2010
- 资助金额:
$ 39.6万 - 项目类别:
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
用于治疗安非他明滥用/疾病的新型功能选择性血清素 5HT2 药物
- 批准号:
8531900 - 财政年份:2010
- 资助金额:
$ 39.6万 - 项目类别:
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
用于治疗安非他明滥用/疾病的新型功能选择性血清素 5HT2 药物
- 批准号:
8715749 - 财政年份:2010
- 资助金额:
$ 39.6万 - 项目类别:
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/Disorder
用于治疗安非他明滥用/疾病的新型功能选择性血清素 5HT2 药物
- 批准号:
8144930 - 财政年份:2010
- 资助金额:
$ 39.6万 - 项目类别:
Translational Genetics and Dopamine Signaling in Sensitivity to Amphetamines
安非他明敏感性中的转化遗传学和多巴胺信号传导
- 批准号:
7675601 - 财政年份:2009
- 资助金额:
$ 39.6万 - 项目类别:
Simultaneous determination of ephedrines, amphetamines, cocaine, cocaine metabolites, and opiates and interaction in the rat
大鼠体内麻黄碱、安非他明、可卡因、可卡因代谢物和阿片类药物的同时测定及其相互作用
- 批准号:
17590585 - 财政年份:2005
- 资助金额:
$ 39.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Study for practical use of two chiral analyses of amphetamines by gas chromatography-mass spectrometry
气相色谱-质谱法对苯丙胺两种手性分析的实用化研究
- 批准号:
17590588 - 财政年份:2005
- 资助金额:
$ 39.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clinical Pharmacology of 3,4-Methylenedioxy Amphetamines
3,4-亚甲二氧基安非他明的临床药理学
- 批准号:
6870119 - 财政年份:2004
- 资助金额:
$ 39.6万 - 项目类别:














{{item.name}}会员




